

Supplemental Table 1

Cycle A - CEOP Dose Modifications for Hematologic Toxicities*

Blood Count on Day of Treatment	Duration of Toxicity	Action	Dose upon restart
Platelet < 75,000/ μ L or ANC < 700/ mm^3	1 week	Hold dose and recheck labs in 1 week	If labs recovered, then keep dose the same.
	2 weeks	Hold dose and recheck labs in 1 week	If labs recovered, then keep dose the same.
	3 weeks	Hold dose and recheck labs until adequate, then give reduced dose.	Reduce CEOP doses 25% for next Cycle A
	4 weeks or 2 nd recurrence	Stop therapy	

* Course Once, Cycle A: Prior to receiving the initial dose of cyclophosphamide, etoposide, vincristine and prednisone (CEOP), patients must meet the laboratory parameters outlined in the eligibility criteria.

Cycle B Pralatrexate Dose Modifications for Hematologic Toxicities

Blood Count on Day of Treatment	Duration of Toxicity	Action	Dose upon restart
Platelet < 50,000/ μ L	1 week	Omit dose, recheck labs in 1 week.	If labs adequate, continue at 30 mg/m^2 .
	2 weeks	Omit dose, recheck labs in 1 week	If labs adequate, reduce dose to 20 mg/m^2 .
	3 weeks	Stop therapy	
ANC < 700 μ L and no fever	1 week	Omit dose, recheck labs in 1 week.	If labs adequate, continue at 30 mg/m^2 .
ANC < 700 μ L with fever	1 week	Omit dose, give G-CSF or GM-CSF support	Continue at 30 mg/m^2 with G-CSF support.
	2 weeks or recurrence	Omit dose, give G-CSF or GM-CSF support	Reduce dose to 20 mg/m^2 with G-CSF support